DCM
CRVS icon

Difesa Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Difesa Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$22.9K – 11
2023
Q2 		$22.9K Buy
+10,000
New +$20.8K 0.06% 32

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TL
TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Difesa Capital Management's CRVS Position: Q3 2023 in Review

Difesa Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2023, closing a stake of 10,000 shares — an estimated $22.9K sold.

Difesa Capital Management first reported a position in CRVS in Q2 2023 and held it in 1 quarter. The position peaked at $22.9K in Q2 2023. 52 funds tracked by Wall St. Rank hold CRVS as of Q3 2023.

  • Difesa Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 10,000 Corvus Pharmaceuticals shares in Q3 2023, an estimated $22.9K.
  • Difesa Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Difesa Capital Management's Corvus Pharmaceuticals position peaked at $22.9K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.